Credit: Shutterstock photoKindred Biosciences, a biotech developing pet therapeutics for pain and severe itching, raised $53 million by offering 7.5 million shares (up from 5.8 million) at $7, the midpoint of the range of $6 to $8. Kindred Biosciences plans to list on the NASDAQ under the symbol KIN. Kindred Biosciences initially filed confidentially on 10/2/2013. BMO Capital Markets and Guggenheim Securities acted as joint bookrunners on the deal.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
